Bexarotene - BlackBoxRX.com

Bexarotene

Contraindication in Pregnancy due to Teratogenecity associated with retinoid class of drugs.

MONITORING RECOMMENDATIONS RELATED TO BLACK BOX DATA

Negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within one week prior to therapy. Repeat pregnancy test at monthly intervals during therapy
Effective contraception used for 1 month prior to initiation of therapy, during therapy and > 1 month after drug discontinued.
See full package insert for complete information

Package Inserts

Bexarotene

Updated July 2009

Disclaimer: This information presents a SUMMARY of Black Box data from product information labeling and does not address additional warnings, precautions, or other important safety data in the product insert. Patient care decisions SHOULD NOT be made without reviewing the most recent product information insert, which may be obtained from the manufacturer. This table may not be complete as it was prepared using product information from package inserts. It is periodically updated with supplemental information from FDA safety alerts, the FDA labeling announcements, and new drug approvals.

Formweb is a product of Formulary Productions, LLC. Visit our website at www.formweb.com for more information on online formularies featuring Black Box Warnings.
901-767-3000